

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 September 2007 (07.09.2007)

PCT

(10) International Publication Number
WO 2007/101007 A8

(51) International Patent Classification:

A61K 31/54 (2006.01) C07D 279/10 (2006.01)
A61K 31/50 (2006.01) C07D 295/00 (2006.01)

(21) International Application Number:

PCT/US2007/062406

(22) International Filing Date:

20 February 2007 (20.02.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/776,145 23 February 2006 (23.02.2006) US

(71) Applicant (for all designated States except US): **NEUROGEN CORPORATION** [US/US]; 35 Northeast Industrial Road, Branford, Connecticut 06405 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PETERSON, John, M.** [US/US]; 119 Maple Avenue, Durham, Connecticut 06422 (US). **LI, Guiying** [US/US]; 76 Rutgers Place, Apt. 1, Riveredge, New Jersey 07661 (US). **IHLE, David, C.** [US/US]; 242 Greens Farm Road, Branford, Connecticut 06405 (US). **HODGETTS, Kevin, J.** [GB/US]; 224 Reservoir Road, Killingworth, Connecticut 06419 (US). **GUO, Qin** [US/US]; 118 Maple Terrace, Waterford, Connecticut 06385 (US). **GE, Ping** [US/US]; 718R Higganum Road, Durham, Connecticut 06422 (US). **HUTCHISON, Alan, J.** [US/US]; 27 Allison Drive, Madison, Connecticut 06443 (US).(74) Agent: **KADLECEK, Ann**; Neurogen Corporation, 35 Northeast Industrial Road, Branford, Connecticut 06405 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:
16 October 2008(48) Date of publication of this corrected version:
16 July 2009(15) Information about Correction:
see Notice of 16 July 2009

(54) Title: ARYL SULFONYL HETEROCYCLES

(57) Abstract: Compounds of Formula (I) are provided in which the variables are as described herein. Such compounds may be used to modulate bradykinin receptor activity *in vivo* or *in vitro*, and are particularly useful in the treatment of conditions responsive to B₁ modulation in humans, domesticated companion animals and livestock animals, including inflammation and pain. Pharmaceutical compositions andmethods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various *in vitro* assays.

WO 2007/101007 A8